Hyaluronic Acid Binding Protein 2 Is a Novel Regulator of Vascular Integrity

Objective—The disruption of the endothelial cell barrier is a critical feature of inflammation and an important contributing factor to acute lung injury (ALI), an inflammatory condition that is a major cause of morbidity and mortality in critically ill patients. We evaluated the role of the extracellular serine protease, hyaluronic acid binding protein 2 (HABP2), in vascular barrier regulation. Methods and Results—By using immunoblot and immunohistochemical analysis, we observed that lipopolysaccharide (LPS) induces HABP2 expression in murine lung endothelium in vivo and in human pulmonary microvascular endothelial cells (ECs) in vitro. High-molecular-weight hyaluronan (HMW-HA, approximately 1×106 Da) decreased HABP2 protein expression in human pulmonary microvascular ECs and decreased purified HABP2 enzymatic activity, whereas low-molecular-weight HA (LMW-HA, approximately 2500 Da) increased these activities. The effects of LMW-HA, but not HMW-HA, on HABP2 activity were inhibited with a peptide of the polyanion-binding domain of HABP2. Silencing (small interfering RNA) HABP2 expression augmented HMW-HA–induced EC barrier enhancement and inhibited LPS and LMW-HA–mediated EC barrier disruption, results that were reversed with overexpression of HABP2. Silencing protease-activated receptor 1 and 3, RhoA, or Rho kinase expression attenuated LPS-, LMW-HA–, and HABP2-mediated EC barrier disruption. By using murine models of acute lung injury, we observed that LPS- and ventilator-induced pulmonary vascular hyperpermeability was significantly reduced with vascular silencing (small interfering RNA) of HABP2. Conclusion—HABP2 negatively regulates vascular integrity via activation of protease-activated receptor/RhoA/Rho kinase signaling and represents a potentially useful therapeutic target for syndromes of increased vascular permeability.

[1]  K. Preissner,et al.  High negative charge‐to‐size ratio in polyphosphates and heparin regulates factor VII‐activating protease , 2009, The FEBS Journal.

[2]  T. van der Poll Tissue factor as an initiator of coagulation and inflammation in the lung , 2008, Critical care.

[3]  J. Gutkind,et al.  Protein Kinase C-related Kinase and ROCK Are Required for Thrombin-induced Endothelial Cell Permeability Downstream from Galpha12/13 and Galpha11/q , 2008 .

[4]  I. Wilhelm,et al.  Identification of protease-activated receptor-4 (PAR-4) in puromycin-purified brain capillary endothelial cells cultured on Matrigel , 2008, Neurochemistry International.

[5]  M. Matthay,et al.  Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury , 2008, Critical care.

[6]  K. Preissner,et al.  Factor VII-activating protease (FSAP): Vascular functions and role in atherosclerosis , 2008, Thrombosis and Haemostasis.

[7]  F. Vitzthum,et al.  Factor VII-activating protease in patients with acute deep venous thrombosis. , 2008, Thrombosis research.

[8]  R. Salgia,et al.  CD44 Regulates Hepatocyte Growth Factor-mediated Vascular Integrity , 2007, Journal of Biological Chemistry.

[9]  K. Preissner,et al.  Plasminogen Activator Inhibitor-1 Is an Inhibitor of Factor VII-activating Protease in Patients with Acute Respiratory Distress Syndrome* , 2007, Journal of Biological Chemistry.

[10]  K. Preissner,et al.  Raised protein levels and altered cellular expression of factor VII activating protease (FSAP) in the lungs of patients with acute respiratory distress syndrome (ARDS) , 2007, Thorax.

[11]  A. Malik,et al.  Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization , 2007, Proceedings of the National Academy of Sciences.

[12]  P. Parsons,et al.  Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome* , 2006, Critical care medicine.

[13]  A. Guenther,et al.  Elevated protein levels and altered cellular expression of factor VII-activating protease (FSAP) in the lungs of patients with acute respiratory distress syndrome (ARDS) , 2007 .

[14]  K. Preissner,et al.  The G534E polymorphism of the gene encoding the factor VII–activating protease is associated with cardiovascular risk due to increased neointima formation , 2006, The Journal of experimental medicine.

[15]  Shwu-Fan Ma,et al.  Transactivation of Sphingosine 1-Phosphate Receptors Is Essential for Vascular Barrier Regulation , 2006, Journal of Biological Chemistry.

[16]  T. Dörner,et al.  Gene polymorphisms implicated in influencing susceptibility to venous and arterial thromboembolism: Frequency distribution in a healthy German population , 2006, Thrombosis and Haemostasis.

[17]  M. Schaller,et al.  Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome , 2006 .

[18]  K. Preissner,et al.  A positively charged cluster in the epidermal growth factor-like domain of Factor VII-activating protease (FSAP) is essential for polyanion binding. , 2006, The Biochemical journal.

[19]  K. Preissner,et al.  Extracellular RNA is a natural cofactor for the (auto-)activation of Factor VII-activating protease (FSAP). , 2005, The Biochemical journal.

[20]  S. Humphries,et al.  The factor VII activating protease G511E (Marburg) variant and cardiovascular risk. , 2004 .

[21]  J. A. Barnes,et al.  Protease activated receptors in cardiovascular function and disease , 2004, Molecular and Cellular Biochemistry.

[22]  N. Bunnett,et al.  Protease-activated receptors: contribution to physiology and disease. , 2004, Physiological reviews.

[23]  C. Bai,et al.  Inhibition of inflammatory responses by ambroxol, a mucolytic agent, in a murine model of acute lung injury induced by lipopolysaccharide , 2004, Intensive Care Medicine.

[24]  Nikolina Radulovich,et al.  Novel candidate tumor marker genes for lung adenocarcinoma , 2002, Oncogene.

[25]  J. Römisch,et al.  Factor VII Activating Protease (FSAP): A Novel Protease in Hemostasis , 2002, Biological chemistry.

[26]  A. Verin,et al.  Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. , 2001, The Journal of clinical investigation.

[27]  K. Preissner,et al.  Factor VII and single-chain plasminogen activator-activating protease: activation and autoactivation of the proenzyme. , 2001, European journal of biochemistry.

[28]  W. Kiosses,et al.  Regulation of the small GTP‐binding protein Rho by cell adhesion and the cytoskeleton , 1999, The EMBO journal.

[29]  I Maruyama,et al.  Biology of endothelium , 1998, Lupus.

[30]  T. Tobe,et al.  Purification and characterization of a novel hyaluronan-binding protein (PHBP) from human plasma: it has three EGF, a kringle and a serine protease domain, similar to hepatocyte growth factor activator. , 1996, Journal of biochemistry.